PaxMedica is a clinical-stage biopharmaceutical company developing PAX-101, a treatment targeting the core symptoms of Autism Spectrum Disorder (ASD) by modulating sensory processing and social interaction challenges. The company aims to provide a pharmacologic solution for the unmet medical needs of individuals with ASD, where currently no approved treatments exist.
Funding
$7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Currently, there are no FDA-approved pharmacologic treatments that address the core symptoms of Autism Spectrum Disorder (ASD), leaving a significant unmet need for individuals and families affected by this condition. ASD presents challenges in sensory processing, social interaction, and communication, impacting daily life and overall well-being.
Solution
PaxMedica is a clinical-stage biopharmaceutical company focused on developing PAX-101, an innovative therapeutic approach to treat the underlying causes and symptoms of ASD. PAX-101 aims to modulate sensory processing and improve social interaction challenges associated with ASD. By targeting these core areas, PaxMedica seeks to provide a pharmacologic solution that can improve the lives of individuals with autism, allowing them to integrate their behavior more successfully with others. The company's pipeline focuses on neurodevelopmental disorders, with the goal of bringing hope and transformative change to those affected by ASD.
Target Audience
The primary target audience includes individuals diagnosed with Autism Spectrum Disorder, their families, and healthcare professionals specializing in neurodevelopmental disorders.
Features
- PAX-101: A novel therapeutic in clinical development for the treatment of Autism Spectrum Disorder.
- Focus on modulating sensory processing to address sensory-related behaviors associated with ASD.
- Designed to improve social interaction and communication skills in individuals with ASD.
- Potential to eliminate, reduce, or modulate troublesome aspects of sensory and relating behaviors.
- Investigating PAX-101 for the treatment of Human African Trypanosomiasis (HAT), with potential for a Priority Review Voucher (PRV) upon FDA approval.